![Terry O’Neal](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Terry O’Neal is the founder of jCyte, Inc., which was founded in 2012.
He holds the title of Chief Administrative Officer at jCyte, Inc. Currently, Mr. O’Neal is the Chief Operating Officer at Ray Therapeutics, Inc.
Posizioni attive di Terry O’Neal
Società | Posizione | Inizio |
---|---|---|
jCyte, Inc.
![]() jCyte, Inc. Medical/Nursing ServicesHealth Services jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA. | Fondatore | 01/01/2012 |
Ray Therapeutics, Inc.
![]() Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
jCyte, Inc.
![]() jCyte, Inc. Medical/Nursing ServicesHealth Services jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA. | Health Services |
Ray Therapeutics, Inc.
![]() Ray Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation. | Commercial Services |
- Borsa valori
- Insiders
- Terry O’Neal